Enhancing Balance and Mobility in Incomplete Spinal Cord Injury

Sponsor
Ankara City Hospital Bilkent (Other)
Overall Status
Completed
CT.gov ID
NCT06137443
Collaborator
(none)
5
1
1
10
0.5

Study Details

Study Description

Brief Summary

The goal of this clinical trial is to compare the effects of balance therapy with an overground gait trainer in incomplete spinal cord injury (SCI). The main questions it aims to answer are:

  • Is balance therapy with an overground gait trainer effective in improving functional ambulation in SCI?

  • Is balance therapy with an overground gait trainer effective in enhancing Activities of Daily Living in SCI?

Participants treated with either:

• Overground gait trainer along with conventional exercise therapy

Condition or Disease Intervention/Treatment Phase
  • Device: Balance Training
N/A

Detailed Description

Background: Spinal Cord Injury (SCI) and similar pathologies not only negatively affect a person's ability to walk but also have adverse effects on their participation in social, vocational, and recreational activities. The correction of walking impairments resulting from SCI is one of the most important goals of rehabilitation, as it is essential for a person's social and vocational integration. When considering balance function, the use of challenging balance and walking exercises at an adequate level is necessary to trigger motor learning. Ensuring the patient's safety is the primary priority when using advanced balance and walking exercises based on the patient's current condition. In this study, Andago V2.0 (Hocoma AG, Volketswil, Switzerland) has been preferred for ensuring safety by adapting to patient movements. The main objective of the study was to assess the impact of Andago on balance in patients with motor incomplete SCI. The secondary aim was to evaluate its influence on quality of life and independence. Methods: The study included five participants who were over 18 years of age and had experienced a spinal injury within the past year. These participants were classified as AIS D (American Spinal Injury Association Impairment Scale). Patients underwent eight-week treatment, with walking and balance exercises on Andago performed three days a week. In addition, conventional in-bed exercises, including stretching, strengthening, and mobility exercises, were administered for 40 minutes, two days a week. Modified Borg Scale (MBS), Ten-Meter Walking Test (10MWT), Timed Up and Go Test (TUG), Walking Index in Spinal Cord Injury II (WISCI II), Berg Balance Scale (BBS), Visual Analogue Scale (VAS) for fear of falling, Spinal Cord Independence Measure (SCIM III), World Health Organization Quality of Life Scale-Short Form (WHOQOL - BREF) were used for evaluation.

Study Design

Study Type:
Interventional
Actual Enrollment :
5 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Enhancing Balance and Mobility in Incomplete Spinal Cord Injury With an Overground Gait Trainer
Actual Study Start Date :
Jan 1, 2022
Actual Primary Completion Date :
Nov 1, 2022
Actual Study Completion Date :
Nov 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Balance Training

The study included five participants who were over 18 years of age and had experienced a spinal injury within the past year. These participants were classified as AIS D (American Spinal Injury Association Impairment Scale). Patients underwent treatment for eight weeks, with walking and balance exercises on Andago performed three days a week. In addition, conventional in-bed exercises, including stretching, strengthening, and mobility exercises, were administered for 40 minutes, two days a week.

Device: Balance Training
Patients underwent treatment for eight weeks, with walking and balance exercises on Andago performed three days a week. In addition, conventional in-bed exercises, including stretching, strengthening, and mobility exercises, were administered for 40 minutes, two days a week.

Outcome Measures

Primary Outcome Measures

  1. Berg Balance Scale [11 months]

    Berg Balance Scale for balance assessment

Secondary Outcome Measures

  1. Ten-Meter Walking Test [11 months]

    Ten-Meter Walking Test for overground walking speed assessment

  2. Timed Up and Go Test [11 months]

    Timed Up and Go Test overground walking assessment

  3. Walking Index in Spinal Cord Injury II [11 months]

    Walking Index in Spinal Cord Injury II for walking independence level assessment

  4. Modified Borg Scale [11 months]

    Modified Borg Scale for subjective fatigue assessment

  5. Visual Analogue Scale [11 months]

    Visual Analogue Scale (VAS) for fear of falling assessment

  6. Spinal Cord Independence Measure (SCIM III) [11 months]

    Spinal Cord Independence Measure (SCIM III) for activity of daily living assessment

  7. World Health Organization Quality of Life Scale-Short Form (WHOQOL - BREF) [11 months]

    World Health Organization Quality of Life Scale-Short Form (WHOQOL - BREF) for quality of life assessment

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Spinal Cord Injured below T4

  • Time from injury < 1 year

  • D level on AIS (American Spinal Injury Association Impairment Scale)

  • Patients with spinal stabilization

Exclusion Criteria:
  • Osteoporosis

  • An implanted electronic device

  • other neurological diseases

  • Cardio-pulmonary diseases

  • Orthopedic diseases

Contacts and Locations

Locations

Site City State Country Postal Code
1 Ankara City Hospital Ankara Turkey 06800

Sponsors and Collaborators

  • Ankara City Hospital Bilkent

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Ankara City Hospital Bilkent
ClinicalTrials.gov Identifier:
NCT06137443
Other Study ID Numbers:
  • AnkaraCHBilkent-PMR-MSS-01
First Posted:
Nov 18, 2023
Last Update Posted:
Nov 18, 2023
Last Verified:
Nov 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 18, 2023